Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring in Prostate Cancer to Improve the Possibilities for Intensity Modulated RadioTherapy (IMRT) Dose Escalation

This study has been terminated.
(Study abandoned.)
Sponsor:
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00122252
First received: July 20, 2005
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

The clinical outcome after external beam irradiation for prostate cancer is disappointing in the advanced tumor stages. There are indications that an increase in radiation dose to the tumor will improve outcome significantly, especially to the biologically active tumour parts within the cancer area. Until recently no imaging equipment was available to define both the anatomic and biologically active tumor parts. Now, at the Center for Biological Imaging and Adaptive Radiotherapy, equipment is at hand that will be able to visualise the areas mentioned above. When combining the data of these imaging modalities it might be possible to create an optimised irradiation plan. This study is a planning study in which, on 15 patients, the different anatomical and biological imaging data per patient will be evaluated, matched and finally a theoretical improved irradiation treatment plan will be made. This research complies with the current opinion on radiation development. Progress in functional imaging is likely to provide the tools required for individualised risk-adapted radiotherapy.


Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Biological Imaging for Optimising CTV and GTV Contouring in Prostate Cancer to Improve the Possibilities for IMRT Dose Escalation

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Estimated Enrollment: 20
Study Start Date: May 2004
Study Completion Date: February 2007
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • Histologically proven prostate adenocarcinoma

Exclusion Criteria:

  • Previous treatment for prostate cancer
  • Contraindications to magnetic resonance imaging (MRI)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00122252

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Matthew Parliament, MD Cross Cancer Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00122252     History of Changes
Other Study ID Numbers: GU-6-0045
Study First Received: July 20, 2005
Last Updated: December 8, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
prostate cancer
radiotherapy
biological imaging

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on August 27, 2014